Neos Therapeutics, Inc.
(NASDAQ : NEOS)

( )
NEOS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
0.00%17.512.0%$143.77m
JAZZJazz Pharmaceuticals Plc
0.23%136.922.3%$116.03m
ICPTIntercept Pharmaceuticals, Inc.
-0.46%109.3418.6%$97.75m
SAGESAGE Therapeutics, Inc.
1.35%158.848.8%$92.54m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-2.26%165.026.3%$89.59m
HZNPHorizon Pharma plc
0.11%26.877.3%$84.75m
PRGOPerrigo Co. Plc
-0.11%46.746.8%$65.48m
ICLRICON Plc
0.56%133.624.1%$57.47m
UTHRUnited Therapeutics Corporation
-0.42%120.2914.3%$56.84m
MNKMallinckrodt Plc
-2.22%21.6021.0%$51.07m
PTLAPortola Pharmaceuticals, Inc.
0.31%32.077.6%$41.99m
AERIAerie Pharmaceuticals, Inc.
-2.80%45.516.9%$37.81m
ENDPEndo International Plc
-0.84%8.268.9%$37.51m
MYOKMyoKardia, Inc.
-4.49%51.872.4%$34.79m
MDCOMedicines Company
0.68%26.7621.8%$30.83m

Company Profile

Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.